Trial Profile

Phase 1 study evaluating the safety, tolerability and pharmacokinetics of single-ascending doses (SAD) and multiple-ascending doses (MAD) of ORX142 in healthy volunteers

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 23 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Jun 2025 According to a Centessa Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) has cleared the IND to initiate a Phase 1 clinical study of ORX142 in healthy volunteers, The Company plans to initiate the first-in-human Phase 1 clinical study imminently, with clinical data expected this year, which is expected to enable a dose selection for planned studies evaluating ORX142 in patients.
18 Nov 2024 New trial record
12 Nov 2024 According to a Centessa Pharmaceuticals media release, Clinical data in healthy volunteers planned for 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com